DE69801660T2 - Lokale behandlung von psoriasis unter verwendung neutralisierender antikörper gegen il-8 - Google Patents

Lokale behandlung von psoriasis unter verwendung neutralisierender antikörper gegen il-8

Info

Publication number
DE69801660T2
DE69801660T2 DE69801660T DE69801660T DE69801660T2 DE 69801660 T2 DE69801660 T2 DE 69801660T2 DE 69801660 T DE69801660 T DE 69801660T DE 69801660 T DE69801660 T DE 69801660T DE 69801660 T2 DE69801660 T2 DE 69801660T2
Authority
DE
Germany
Prior art keywords
psoriasis
antibodies against
neutralizing antibodies
local treatment
biological activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69801660T
Other languages
English (en)
Other versions
DE69801660D1 (de
Inventor
Q Ye
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yes Biotech Laboratories Ltd
Original Assignee
Yes Biotech Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yes Biotech Laboratories Ltd filed Critical Yes Biotech Laboratories Ltd
Application granted granted Critical
Publication of DE69801660D1 publication Critical patent/DE69801660D1/de
Publication of DE69801660T2 publication Critical patent/DE69801660T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69801660T 1997-06-23 1998-06-23 Lokale behandlung von psoriasis unter verwendung neutralisierender antikörper gegen il-8 Expired - Lifetime DE69801660T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN97112184A CN1068524C (zh) 1997-06-23 1997-06-23 一种治疗顽症牛皮癣的药物
PCT/CA1998/000604 WO1998058671A1 (en) 1997-06-23 1998-06-23 Topical treatment of psoriasis using neutralizing antibodies to il-8

Publications (2)

Publication Number Publication Date
DE69801660D1 DE69801660D1 (de) 2001-10-18
DE69801660T2 true DE69801660T2 (de) 2002-06-06

Family

ID=5172124

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69801660T Expired - Lifetime DE69801660T2 (de) 1997-06-23 1998-06-23 Lokale behandlung von psoriasis unter verwendung neutralisierender antikörper gegen il-8

Country Status (9)

Country Link
US (1) US20030077283A1 (de)
EP (1) EP0991423B1 (de)
CN (1) CN1068524C (de)
AT (1) ATE205401T1 (de)
AU (1) AU727937B2 (de)
CA (1) CA2291144C (de)
DE (1) DE69801660T2 (de)
ES (1) ES2164434T3 (de)
WO (1) WO1998058671A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030068319A1 (en) * 2001-03-23 2003-04-10 Menashe Bar-Eli Methods for inhibition of angiogenesis, tumor growth and metastasis by fully human anti-IL8 and anti-MUC18 in diverse types of tumors
FR2830449B1 (fr) * 2001-10-05 2004-04-23 Fabre Pierre Dermo Cosmetique Utilisation du tazarotene pour la preparation d'un vernis a ongles pour le traitement et/ou la prevention du psoriasis et un vernis a ongles le contenant
US7282568B2 (en) 2002-12-16 2007-10-16 Medarex, Inc. Human monoclonal antibodies against interleukin 8 (IL-8)
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
WO2009041643A1 (ja) 2007-09-26 2009-04-02 Chugai Seiyaku Kabushiki Kaisha Cdrのアミノ酸置換により抗体の等電点を改変する方法
ES2661310T3 (es) * 2009-03-09 2018-03-28 Bioatla, Llc Proteínas mirac
EP4231014A3 (de) 2010-11-30 2024-03-20 Chugai Seiyaku Kabushiki Kaisha Antigenbindende moleküle zur wiederholten bindung an mehrere antigenmoleküle
US11236168B2 (en) 2012-08-24 2022-02-01 Chugai Seiyaku Kabushiki Kaisha Mouse FcγammaRII-specific Fc antibody
KR102318483B1 (ko) 2013-04-02 2021-10-27 추가이 세이야쿠 가부시키가이샤 Ｆｃ영역 개변체
CN105521489A (zh) * 2014-09-28 2016-04-27 徐州逸仕生物技术有限公司 抗人TNF-αIgY抗体及其治疗皮肤疾病的应用
MY181199A (en) 2014-12-19 2020-12-21 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
CN107108729A (zh) 2015-02-05 2017-08-29 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il‑8‑结合抗体，及其应用
RO130965A8 (ro) * 2015-10-16 2017-06-30 Romvac Company S.A. Producerea şi utilizarea oului hiperimun personalizat () în tratamentul psoriazisului
US11359009B2 (en) 2015-12-25 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
KR20230079499A (ko) 2016-08-05 2023-06-07 추가이 세이야쿠 가부시키가이샤 Il-8 관련 질환의 치료용 또는 예방용 조성물
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
JP2019535829A (ja) 2016-11-21 2019-12-12 エイリオン セラピューティクス， インコーポレイテッド 大型薬剤の経皮送達
EP3737696A1 (de) 2018-01-12 2020-11-18 Bristol-Myers Squibb Company Kombinationstherapie mit anti-il-8-antikörpern und anti-pd-1-antikörpern zur behandlung von krebs
CN116327926A (zh) 2018-03-15 2023-06-27 中外制药株式会社 对寨卡病毒具有交叉反应性的抗登革热病毒抗体及使用方法
CN109481674A (zh) * 2018-11-14 2019-03-19 大连亚维药业有限公司 一种生物无菌乳膏药物的生产方法
WO2023192478A1 (en) 2022-04-01 2023-10-05 Bristol-Myers Squibb Company Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4364933A (en) * 1979-12-04 1982-12-21 Ortho Pharmaceutical Corporation Monoclonal antibody to a human thymocyte antigen and methods of preparing same
GB9009548D0 (en) * 1990-04-27 1990-06-20 Celltech Ltd Chimeric antibody and method
US5440021A (en) * 1991-03-29 1995-08-08 Chuntharapai; Anan Antibodies to human IL-8 type B receptor
EP0563487A1 (de) * 1992-03-31 1993-10-06 Laboratoire Europeen De Biotechnologie S.A. Monoklonale Antikörper gegen den Interferonrezeptor, mit neutralisierender Aktivität gegen Typ I-Interferon
US5707621A (en) * 1994-08-31 1998-01-13 Chugai Pharmaceutical Co., Ltd. Supression of nephritis-induced protein excretion by anti-IL-8
JPH08277299A (ja) * 1995-04-06 1996-10-22 Fujirebio Inc 抗ｉｌ−８抗体、抗ｉｌ−８モノクローナル抗体を産生するハイブリドーマ及び該抗体を用いたｉｌ−８の測定方法
AU739058B2 (en) * 1996-11-08 2001-10-04 Biogen Idec Inc. Identification of unique binding interactions between certain antibodies and the human B7.1 and B7.2 co-stimulatory antigens

Also Published As

Publication number Publication date
AU8096298A (en) 1999-01-04
ATE205401T1 (de) 2001-09-15
AU727937B2 (en) 2001-01-04
CA2291144A1 (en) 1998-12-30
WO1998058671A1 (en) 1998-12-30
CA2291144C (en) 2001-07-03
CN1068524C (zh) 2001-07-18
EP0991423A1 (de) 2000-04-12
CN1203105A (zh) 1998-12-30
DE69801660D1 (de) 2001-10-18
US20030077283A1 (en) 2003-04-24
ES2164434T3 (es) 2002-02-16
EP0991423B1 (de) 2001-09-12

Similar Documents

Publication Publication Date Title
DE69801660T2 (de) Lokale behandlung von psoriasis unter verwendung neutralisierender antikörper gegen il-8
DE60033530D1 (de) Humane antikörper gegen ctla-4 und deren verwendungen
TR200100922T2 (tr) Aktif maddelerin akciğerler yolu ile tatbik edilmesi.
EA200100721A1 (ru) Производное габапентина для предупреждения и лечения висцеральной боли
BR0111898A (pt) Métodos de tratamento de doenças de proliferação celular, e de um distúrbio associado com a atividade de cinesina ksp, método de inibição da cinesina ksp, composto, método de triagem de moduladores da cinesina kps, e, método de triagem de compostos que se ligam à cinesina ksp
ATE433324T1 (de) Verwendung von glp-1 oder analoge zur behandlung von schlaganfall
ATE279181T1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
ES2194989T3 (es) Composicion adminstrada por via oral, que comprende una toxina de zonula occludens y un agente que tiene una actividad biologica, y su utilizacion.
BR9305783A (pt) Processo para preparar grânulos dispersiveis em água e grânulos dispersíveis em água
ATE215373T1 (de) 21-hydro-6,19-oxidoprogesterone (21oh-60p) und deren verwendung als arzneimittel zur behandlung von glukokortikoidüberschuss
PT1173201E (pt) Metodo para o tratamento de fibrose utilizando um antagonista da subunidade alfa 4 de integrina
DE69120287T2 (de) Aminosulfonylharnstoff-acat-inhibitoren
ES2180774T3 (es) La utilizacion de triacetato de glicerilo para el tratamiento de onicomicosis.
DK1237562T3 (da) Fremgangsmåde til fremstilling af mikania-ekstrakter, som indeholder mikanolid og dihydromikanolid, og anvendelse i behandlingen af prolifererende sygdomme
DE69132575T2 (de) Sampangin-derivate zur verwendung als antimykotische und antimykobakterielle wirkstoffe
DE69626816D1 (de) Verwendung von selegilin zur behandlung von gehörverlust bei säugetieren
EA199800864A1 (ru) Способ лечения при боли, вызванной мигренью
EA199901061A1 (ru) Новые соли врс-пептидов с органопротективной активностью, способ их получения и их использование в терапии
NO984189L (no) FremgangsmÕte for behandling av bipolar forstyrrelse
AP9801416A0 (en) Method Of treating a plant disease.
DE69825395D1 (de) Medikament, behandlungsmethode, prophylaktikum und prophylaxe gegen immunologische erkrankungen von hunden und katzen
DE69936779D1 (de) Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
AR010304A1 (es) Compuestos de dimesilato de cis-1-(3-etoxifenil)-1-4-fenilpiperazin-1-il) -4-metilciclohexano; procedimiento para su preparacion y composicionfarmaceutica
DK0820308T3 (da) Konjugat til behandling af inflammatoriske sygdomme

Legal Events

Date Code Title Description
8364 No opposition during term of opposition